The symptoms include poor growth, vomiting, seizures and developmental delays. The condition is caused due to defects or mutations in the UMP synthase gene that controls the production of an enzyme involved in the breakdown of orotic acid. Effective treatments for the disorder include a low-purine diet, supportive therapies, and medication to prevent complications. The global hereditary orotic aciduria market comprises drugs used for the treatment of the condition. Some of the commonly used medications include 6- azauridine, allopurinol, and sodium phenylbutyrate.
The Hereditary Orotic Aciduria Market Demand is estimated to be valued at US$ 357.9 million in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024 to 2031.
The market is driven by the increasing diagnosis of hereditary disorders through genetic testing and rising awareness about rare genetic diseases.
Key Takeaways
Key players operating in the global hereditary orotic aciduria market are Merck & Co. Inc. and SERB Pharmaceuticals.
Key opportunities in the market include growth in genetic testing capabilities, increasing research on rare diseases and emerging economies providing untapped potential.
North America is expected to continue dominating the global market owing to high healthcare expenditure and awareness. However, Asia Pacific is anticipated to witness the highest growth over the forecast period owing to growing healthcare infrastructure and increasing discretionary spending.
Market Drivers
Increasing diagnostic rate for genetic disorders - Advancements in genetic testing technologies have enabled improved diagnosis of hereditary conditions including orotic aciduria. This is positively impacting the market growth.
Growing awareness about rare genetic diseases - Initiatives by patient advocacy groups and medical organizations are enhancing awareness about rare diseases like hereditary orotic aciduria among the general public as well as healthcare community. This is translating into higher treatment seeking behavior.
Market Restraints
Low prevalence of the disorder - Hereditary orotic aciduria is a rare inherited metabolic disorder with global prevalence estimated to be around 1 in 800,000 live births. The low cases negatively influence the market revenue.
High cost of treatment - Majority of drugs used for the management of orotic aciduria have a high price tag which acts as a barrier, especially in low and middle-income nations.
Segment Analysis
The global hereditary orotic aciduria market is segmented into type, treatment and distribution channel. By type, the market is classified into type I orotic aciduria and type II orotic aciduria. Type I orotic aciduria dominates the segment, accounting for nearly 70% share. It occurs at an early stage and affect severely. By treatment, the market is bifurcated into medication and dietary supplements. Medication form the largest segment owing to growing availability and adoption of allopurinol drug for treatment. By distribution channel, hospitals & retail pharmacies dominate the segment as they are the primary point of contact for patients diagnosis and treatment.
Global Analysis
North America region holds the major share in the global hereditary orotic aciduria market and is expected to remain dominant during the forecast period. Growing patient pool, advanced healthcare infrastructure, presence of major players and increasing awareness regarding rare diseases are driving the North America market. Asia Pacific is estimated to witness the highest growth rate during the forecast period owing to increasing healthcare expenditure, improving accessibility and rising incidence of genetic disorders in developing countries.
Get more insights on Hereditary Orotic Aciduria Market
Comments
0 comment